Get the Stockscreener App
5.34
3.96%
-0.22
After Hours:
5.46
0.12
+2.25%
Outlook Therapeutics Inc stock is traded at $5.34, with a volume of 153.66K.
It is down -3.96% in the last 24 hours and down -27.35% over the past month.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
See More
Previous Close:
$5.56
Open:
$5.59
24h Volume:
153.66K
Relative Volume:
0.69
Market Cap:
$129.75M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-21.36
EPS:
-0.25
Net Cash Flow:
$-47.10M
1W Performance:
-4.30%
1M Performance:
-27.35%
6M Performance:
-55.28%
1Y Performance:
+20.81%
1-Day Range:
$5.33
$5.73
1-Week Range:
$5.22
$5.87
52-Week Range:
$4.344
$18.00
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Great Point Partners LLC Raises Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
(OTLK) Investment Analysis - Stock Traders Daily
Great Point Partners LLC Grows Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat
Checking in on Outlook Therapeutics Inc (OTLK) after recent insiders movement - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing Outlook Therapeutics Inc (OTLK)’s Performance - The Dwinnex
A year in review: Outlook Therapeutics Inc (OTLK)’s performance in the last year - US Post News
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series - ForexTV.com
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series - StockTitan
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - GlobeNewswire
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - StockTitan
OTLKOutlook Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Outlook Therapeutics Inc (OTLK) Becoming More Attractive for Investors - Knox Daily
Private equity firms are Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners and were rewarded after market cap rose by US$30m last week - Simply Wall St
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Outlook Therapeutics Inc [OTLK] Shares Jump Approximately 62.65% Over the Year - Knox Daily
Outlook Therapeutics completes NORSE EIGHT enrollment - Investing.com
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial - GlobeNewswire
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial - StockTitan
Outlook Therapeutics (NASDAQ:OTLK) Price Target Lowered to $33.00 at Ascendiant Capital Markets - Defense World
Ascendiant Capital Markets Lowers Outlook Therapeutics (NASDAQ:OTLK) Price Target to $33.00 - MarketBeat
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
OTLK’s latest rating updates from top analysts. - Knox Daily
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutic - GuruFocus.com
Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles - Seeking Alpha
Outlook Therapeutics Inc [OTLK] Investment Guide: What You Need to Know - Knox Daily
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Forecasted to Earn FY2024 Earnings of ($3.90) Per Share - MarketBeat
Vanguard Group Inc. Has $4.08 Million Stock Holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Vanguard Group Inc. Sells 6,219,100 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Expected to Post FY2024 Earnings of ($3.90) Per Share - Defense World
Chardan Capital Reiterates “Buy” Rating for Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Outlook Therapeutics (NASDAQ:OTLK) Rating Reiterated by HC Wainwright - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) to Post FY2027 Earnings of $1.17 Per Share, HC Wainwright Forecasts - Defense World
Outlook Therapeutics (NASDAQ:OTLK) Stock Rating Reaffirmed by Chardan Capital - MarketBeat
Brokerages Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Price Target at $46.43 - MarketBeat
OTLK (Outlook Therapeutics) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com
Outlook Therapeutics, Inc. to Post FY2027 Earnings of $1.17 Per Share, HC Wainwright Forecasts (NASDAQ:OTLK) - MarketBeat
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of O - GuruFocus.com
HC Wainwright Reiterates "Buy" Rating for Outlook Therapeutics (NASDAQ:OTLK) - MarketBeat
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Q3 2024 Earnings Call Transcript - Insider Monkey
Outlook Therapeutics Inc (OTLK) Q3 2024 Earnings Call Transcript - GuruFocus.com
Q3 2024 Outlook Therapeutics Inc Earnings Call Transcript - GuruFocus.com
Investing in Outlook Therapeutics Inc (OTLK): What You Must Know - Knox Daily
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - GlobeNewswire
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - wallstreet:online
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - StockTitan
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - Yahoo Finance
Head-To-Head Review: Mosaic ImmunoEngineering (OTCMKTS:CPMV) & Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - ForexTV.com
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):